dc.contributor.author |
Saen-Oon S. |
|
dc.contributor.author |
Kuno H. |
|
dc.contributor.author |
Hannongbua S. |
|
dc.date.accessioned |
2021-04-05T04:32:29Z |
|
dc.date.available |
2021-04-05T04:32:29Z |
|
dc.date.issued |
2005 |
|
dc.identifier.issn |
8873585 |
|
dc.identifier.other |
2-s2.0-28644442414 |
|
dc.identifier.uri |
https://ir.swu.ac.th/jspui/handle/123456789/15072 |
|
dc.identifier.uri |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-28644442414&doi=10.1002%2fprot.20690&partnerID=40&md5=bdfa20e816813bf3ae48971687134dd4 |
|
dc.description.abstract |
Two-layered and three-layered ONIOM calculations were performed to compare the binding energies of 8-Cl TIBO inhibitor when bound into the human immunodeficiency virus reverse transcriptase binding pocket and a Y181C variant. Both consisted of 20 residues within a radius of 15 Å. A combination of different methods [HP2/6-31G(d), B3LYP/6-31G(d,p), and PM3] were performed to take advantage of ONIOM's layering strategy analysis. The obtained results clearly indicate that the Y181C mutation reduces the binding affinity and stability of the inhibitor by approximately 8-9 kcal/mol as obtained from different combined MO:MO methods. Analyses regarding the energetic components of the interaction and deformation energies for 8-Cl TIBO inhibitor upon binding were also examined extensively. Additional calculations involving the interaction energies between 8-Cl TIBO with individual residues surrounding the binding pocket were performed at MP2/6-31G(d,p) and B3LYP/6-31G(d,p) levels of theory to gain more insight into the energetic differences of wild-type and Y181C mutant type at the atomistic level. © 2005 Wiley-Liss, Inc. |
|
dc.subject |
4,5,6,7 tetrahydroimidazo 8 chloro 5 methyl (3 methyl 2 butenyl)imidazo |
|
dc.subject |
RNA directed DNA polymerase |
|
dc.subject |
RNA directed DNA polymerase inhibitor |
|
dc.subject |
unclassified drug |
|
dc.subject |
analytic method |
|
dc.subject |
article |
|
dc.subject |
binding affinity |
|
dc.subject |
calculation |
|
dc.subject |
comparative study |
|
dc.subject |
complex formation |
|
dc.subject |
drug binding site |
|
dc.subject |
drug protein binding |
|
dc.subject |
energy |
|
dc.subject |
Human immunodeficiency virus 1 |
|
dc.subject |
molecular stability |
|
dc.subject |
mutation |
|
dc.subject |
nonhuman |
|
dc.subject |
priority journal |
|
dc.subject |
quantum chemistry |
|
dc.subject |
wild type |
|
dc.subject |
Amino Acid Substitution |
|
dc.subject |
Dimerization |
|
dc.subject |
HIV-1 |
|
dc.subject |
Kinetics |
|
dc.subject |
Models, Molecular |
|
dc.subject |
Polymorphism, Single Nucleotide |
|
dc.subject |
Protein Structure, Secondary |
|
dc.subject |
Protein Subunits |
|
dc.subject |
Quantum Theory |
|
dc.subject |
Recombinant Proteins |
|
dc.subject |
Reverse Transcriptase Inhibitors |
|
dc.subject |
RNA-Directed DNA Polymerase |
|
dc.subject |
Thermodynamics |
|
dc.subject |
Human immunodeficiency virus |
|
dc.subject |
Human immunodeficiency virus 1 |
|
dc.title |
Binding energy analysis for wild-type and Y181C mutant HIV-1 RT/8-Cl TIBO complex structures: Quantum chemical calculations based on the ONIOM method |
|
dc.type |
Article |
|
dc.rights.holder |
Scopus |
|
dc.identifier.bibliograpycitation |
Proteins: Structure, Function and Genetics. Vol 61, No.4 (2005), p.859-869 |
|
dc.identifier.doi |
10.1002/prot.20690 |
|